Abstract
Background: To elucidate and summarize the safety and efficacy of signal transducer and activator of transcription (STAT) 3 polymorphism in tyrosine kinase inhibitors (TKIs)-treated patients with metastatic renal cell carcinoma (mRCC). Methods: Relevant studies from PubMed, EMBASE and Web of Science were identified and included in this systematic review after elaborate screening. Odds ratios (ORs) with 95% confidence interval (CI) were applied to evaluate the correlation between STAT3 polymorphism and TKIs-induced events in mRCC. Results: It was indicated that STAT3 polymorphism was associated with TKIs-induced events including stomatitis, hand-foot skin reactions (HFSR), and response in mRCC patients treated with TKIs. Considering its safety, STAT3 rs744166 was related to stomatitis development (n=1), and rs4796793 predicted the development and severity of HFSR (n=1). Furthermore, for its efficacy, STAT3 rs4796793, rs744166, and rs989119 were associated with treatment response (n=1). Conclusions: Our systematic review revealed that STAT3 polymorphisms were associated with TKIs-induced safety and efficacy in patients with mRCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
